Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

Moderna and Merck announced positive results from a cancer vaccine trial, causing the company's stock to more than double. However, investors later sold off their shares, erasing some of those gains and reducing the company's value by billions of dollars.